10022612Improving ultrasound penetration and vessel selectabilityClosedCollaborative R&DInnovate UKSupraQ is a non-invasive Cardiac Output (CO) device using Continuous Wave ultrasound. Our technology utilises an ultrasound transducer presented to the suprasternal notch (V-shaped notch at base of neck) to measure blood flow in the ascending aorta. This need has enormous market potential helping over 16 million patients each year. Clinicians currently lack a low cost, simple, reliable, non-invasive haemodynamic monitor to assess the circulatory status of sick non-ventilated patients rapidly and accurately, and then guide their treatment. Protecting patients from haemodynamic errors through improved screening and monitoring would save thousands of lives, improve outcomes and reduce costs. Haemodynamic instability is frequent, resulting in myocardial infarctions, stroke and kidney injury. Complications have clinical and financial consequences; unplanned ICU admissions; longer hospital stay; increased readmissions; increased 30-day mortality; and shorter lifespan after discharge. Prompt diagnosis, particularly in Covid-19 patients, is critical before a circulatory problem becomes severe. Usage would improve patient outcomes, reduce hospital stay, improve utilization of stretched resources and deliver economic benefits. Deltex has vast experience in haemodynamics, its current ultrasound monitoring technology has been repeatedly demonstrated to improve patient outcomes (23 Randomised Controlled Trials and a NICE recommendation).